Loading...
•
Mar 31, 2023
Amneal Q1 2023 Earnings Report
Amneal's Q1 2023 earnings were announced, revealing a net revenue increase and affirming the full year guidance.
Key Takeaways
Amneal Pharmaceuticals reported a strong start to 2023 with a 12% increase in net revenue to $558 million compared to the first quarter of 2022. The company's performance was driven by growth across all three business segments. While the company reported a net loss of $7 million, adjusted EBITDA increased by 16% to $116 million. The company is affirming its full year 2023 guidance.
Net revenue for Q1 2023 reached $558 million, a 12% increase year-over-year.
GAAP net loss was $7 million, with a diluted loss per share of $0.05.
Adjusted EBITDA stood at $116 million, a 16% increase year-over-year.
Adjusted diluted EPS was $0.12, consistent with the first quarter of 2022.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal is affirming its previously provided full year 2023 guidance.
Positive Outlook
- Net revenue between $2.25 billion and $2.35 billion
- Adjusted EBITDA between $500 million and $530 million
- Adjusted diluted EPS between $0.40 and $0.50
- Operating cash flow between $200 million and $230 million
- Capital expenditures between $50 million and $60 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income